閉経後乳がんに対する術前補助療法としての、アナストロゾールとメトロノミックテガフール・ウラシルの併用療法に関する無作為化第II相試験

基本情報

NCT ID: NCT01262274
ステータス: 中止
試験のフェーズ: 第2相
試験タイプ: 介入
目標被験者数: 57
治験依頼者名: Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan

概要

The Aim of this study is to validate a treatment of anastrozole in combination with tegafur-uracil as pre-operative therapy for postmenopausal primary breast cancer. Although pre-operative hormone therapy is a novel therapeutic approach, only hormone therapy has limitation in terms of efficacy. Metronomic chemotherapy, which is the frequent administration of low-dose cytotoxic agents, is not only target tumor cells but also inhibiting angiogenesis. Because there was a report that efficacy of hormone therapy add to metronomic chemotherapy as pre-operative therapy, a randomized phase II trial of anastrozole (ANA) in combination with/without metronomic tegafur-uracil (UFT) as neo-adjuvant for postmenopausal breast cancer will be conducted.

対象疾患

Breast Neoplasms

介入

Anastrozole(DRUG)

Anastrozole plus tegafur-uracil(DRUG)

依頼者（Sponsor）

Translational Research Center For Medical Innovation, Kobe, Hyogo, Japan(OTHER)

Department Of Breast And Endocrine Surgery Graduate School Of Medicine Osaka University(UNKNOWN)

実施施設 (1)

大阪大学医学部附属病院

Osaka, Osaka, Japan